DBC-664 not checked
Duboce Biopharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma
- Main trialPhase 1
- “DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.”In the company’s words, NCT07705035 on ClinicalTrials.gov
Other drugs for Lung Adenocarcinoma
- BNP7787Lantern Pharma Inc. · BioNumerik Pharmaceuticals, Inc. · Phase 2
- SL-28Second Life Therapeutics · Phase 1/2
- PalacaparibAstraZeneca · Phase 1/2
- SaruparibAstraZeneca · Phase 1/2
- Torvutatug samrotecanAstraZeneca · Phase 1/2
- TNG260Tango Therapeutics, Inc. · Phase 1/2
Coming up1
- 1 Apr 2030Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Apr 2030 | DBC-664 in Adult Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026